California Public Employees Retirement System lifted its position in shares of Emergent Biosolutions Inc (NYSE:EBS) by 5.6% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 52,276 shares of the biopharmaceutical company’s stock after buying an additional 2,776 shares during the quarter. California Public Employees Retirement System owned approximately 0.13% of Emergent Biosolutions worth $2,115,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Riverhead Capital Management LLC lifted its stake in shares of Emergent Biosolutions by 102.8% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,542 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Emergent Biosolutions by 23.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 587 shares in the last quarter. First Quadrant L P CA purchased a new position in shares of Emergent Biosolutions during the 3rd quarter valued at $157,000. Meeder Asset Management Inc. lifted its stake in shares of Emergent Biosolutions by 94.7% during the 3rd quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 2,302 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in shares of Emergent Biosolutions during the 3rd quarter valued at $191,000. Institutional investors own 88.44% of the company’s stock.
A number of research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Chardan Capital lifted their target price on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Wells Fargo & Co restated an “outperform” rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th.
In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 31,508 shares of the business’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.77, for a total value of $1,347,597.16. Following the sale, the chief executive officer now owns 215,642 shares in the company, valued at approximately $9,223,008.34. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Fuad El-Hibri sold 40,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $40.37, for a total transaction of $1,614,800.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 206,329 shares of company stock worth $8,892,362. Corporate insiders own 16.50% of the company’s stock.
Shares of Emergent Biosolutions Inc (EBS) opened at $49.60 on Friday. The company has a market cap of $2,050.00, a price-to-earnings ratio of 31.00, a price-to-earnings-growth ratio of 1.01 and a beta of 1.29. Emergent Biosolutions Inc has a one year low of $27.94 and a one year high of $50.14. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.41 by $0.32. The business had revenue of $149.43 million for the quarter, compared to analysts’ expectations of $124.55 million. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.56 EPS. equities analysts forecast that Emergent Biosolutions Inc will post 1.66 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “California Public Employees Retirement System Has $2.12 Million Position in Emergent Biosolutions Inc (EBS)” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://ledgergazette.com/2018/01/19/california-public-employees-retirement-system-has-2-12-million-position-in-emergent-biosolutions-inc-ebs.html.
Emergent Biosolutions Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.